Source comparison
Melanotan-1 Pharmacokinetics: Clearance vs Duration
Melanotan-1 is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), modified at positions 4 and 10 to resist enzymatic degradation by neutral endopeptidase and dipeptidyl peptidase IV. The enzymes that rapidly cleave endogenous α-MSH within minutes
This comparison does not assign a generated winner or score.
- Melanotan-1 is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), modified at positions 4 and 10 to resist enzymatic degradation by neutral endopeptidase and dipeptidyl peptidase IV. The enzymes that rapidly cleave endogenous α-MSH within minutes of secretion. Despite these modifications, afamelanotide still undergoes proteolytic degradation, primarily in the liver and kidneys, with renal clearance as the dominant elimination route. Peak plasma concentration occurs 2–4 hours post-subcutaneous injection, followed by biphasic elimination: an initial rapid distribution phase (t½ ~30 minutes) and a terminal elimination phase (t½ ~40–50 minutes in some studies). By 4–6 hours post-dose, plasma levels are undetectable using standard ELISA methods.
- What matters more than clearance rate is receptor engagement duration. Melanotan-1 binds melanocortin-1 receptors (MC1R) on melanocytes with high affinity, triggering adenylyl cyclase activation and sustained cAMP elevation. That cAMP surge activates protein kinase A, which phosphorylates CREB (cAMP response element-binding protein), initiating transcription of MITF (microphthalmia-associated transcription factor). The master regulator of melanogenesis. MITF then upregulates tyrosinase, TRP-1, and DCT expression, enzymes that synthesize eumelanin over the subsequent 48–72 hours. The peptide itself doesn't need to remain bound to MC1R for this cascade to complete. Receptor activation is the ignition event, not the fuel.
- Our team has reviewed pharmacokinetic data from Clinuvel's afamelanotide trials repeatedly. The pattern is consistent: plasma levels correlate poorly with clinical outcomes like minimal erythema dose (MED) or pigmentation density measured via reflectance spectrophotometry. A single 16 mg subcutaneous implant (used in Scenesse, the FDA-approved formulation) releases afamelanotide over 60 days with undetectable plasma levels beyond day 2–3 post-implantation, yet photoprotection persists throughout the release period. This is receptor biology, not continuous drug exposure.